Drugs in Dev. Neurology
Phase II
India 
Details : As part of a collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bajaj Healthcare Limited Secures SEC-CDSCO Nod for Phase III Trials of Cenobamate
Details : Bajaj is working on a generic version of the anti-seizure medication, cenobamate, as part of its efforts to expand its portfolio in the epilepsy treatment market.
Product Name : Cenobamate-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives USFDA Orphan Drug Designation for Usnoflast to Treat ALS
Details : ZYIL1 (usnoflast) is a novel oral NLRP3 inhibitor, being investigated for the treatment of a rare disease called amyotrophic lateral sclerosis (ALS).
Product Name : ZYIL1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2025
Zydus Receives USFDA Approval for Phase II(b) Trial of Usnoflast in ALS
Details : ZYIL1 (usnoflast) is a novel oral NLRP3 inflammasome inhibitor, being investigated in patients with Amyotrophic Lateral Sclerosis (ALS).
Product Name : ZYIL1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PROSEEK Study Shows No Treatment Benefit of Vodobatinib in Early Parkinson's Disease
Details : K0706 (vodobatinib) is a c-Abl kinase inhibitor, oral capsule small molecule drug candidate, which is currently being evaluated for the treatment of patients with parkinson’s disease.
Product Name : K0706
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
Details : ZYIL1 (usnoflast) is an NLRP3 inhibitor, which is being evaluated in the mid-stage clinical trial studies with the patients for treating amyotrophic lateral sclerosis.
Product Name : ZYIL1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2024
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Suven Life Sciences Breathes New Life Into Drug Discovery Plans
Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
Product Name : SUVN-502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2023
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SPARC Completes Enrolment in PROSEEK, Phase 2 Study of Vodobatinib in Early Parkinson’s Disease
Details : K0706 (vodobatinib) is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. It is being evaluated in patients with Parkinson’s disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.
Product Name : K0706
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Vodobatinib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.
Product Name : SUVN-502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AADvac1 vaccine demonstrates robust antibody response, excellent safety profile and highly significant impact on neurodegeneration in Alzheimer's disease.
Product Name : AADvac1
Product Type : Vaccine
Upfront Cash : Inapplicable
June 14, 2021
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
